The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Official Title: A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma
Study ID: NCT03175172
Brief Summary: The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
Detailed Description: The population for this study will consist of approximately 35 adults with histologically-confirmed MPM (epithelial or biphasic) whose disease has progressed after 1-2 prior anti-cancer therapies.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
UCSF Comprehensive Cancer Center, San Francisco, California, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
University of Chicago Medical Center, Chicago, Illinois, United States
NIH National Cancer Institute, Bethesda, Maryland, United States
Mayo Clinic, Rochester, Minnesota, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States